ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
9 announcements
3B BlackBio Dx sent a Reg 36(1)(b) letter to shareholders providing the weblink to its FY 2025-26 Annual Report ahead of the 54th AGM. No financial figures or business events are disclosed.
3B BlackBio Dx Ltd filed its FY 2025-26 Annual Report with BSE under Regulation 34(1). The report recaps its molecular diagnostics growth and global expansion.
3B BlackBio Dx Ltd issued notice for its 54th AGM on 29 September 2026. Proposed business includes FY26 financials adoption and Rs.5 per share final dividend.
3B BlackBio Dx reported Q1FY27 consolidated revenue of ₹33.49 Cr, up 50% YoY, driven by the Coris BioConcept acquisition. Core MDx business grew 17.4% excluding Coris.
3B BlackBio Dx Ltd reported revenue from operations of ₹33.5 Cr (+50.9% YoY) and net profit of ₹9 Cr (-28.6% YoY) for Q1 FY27.
3B BlackBio reported FY26 consolidated revenue of ₹142 cr and PAT of ₹60 cr, driven by diagnostic growth and contributions from Coris BioConcept and TRUPCR Europe.
3B BlackBio reported strong FY26 consolidated revenue of ₹142cr with a PAT of ₹60cr, driven by European acquisitions despite slower domestic molecular diagnostic growth.
3B BlackBio Dx delivered strong consolidated growth in FY26, driven by the acquisition of Coris BioConcept. Strategy focuses on expanding the Molecular Diagnostics (MDx) portfolio and international market penetration.
3B BlackBio Dx Ltd reported revenue from operations of ₹35.4 Cr (+57.3% YoY) and net profit of ₹9.8 Cr (+22.5% YoY) for Q4 FY26.